About Immucor
Immucor is a company based in United States founded in 1982 was acquired by Werfen in November 2022. Immucor has completed 2 acquisitions, including BioArray Solutions and Organ-i. Immucor operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website immucor.com
- Social LinkedIn X Facebook Instagram YouTube
- Acquired by Werfen (Nov 2022)
- Legal Name Immucor India Private Limited
- Date of Incorporation 10 Mar, 2012
- Jurisdiction Delhi, India
- Annual Revenue₹68.59 Cr
FY 2024 · +12% YoY
- Net Profit₹3.17 Cr
FY 2024 · 5% margin
- EBITDA₹10.02 Cr
FY 2024 · 15% margin
- InvestorsTPG
& 2 more
- Investments & AcquisitionsBioArray Solutions
& 1 more
- Acquired by
Associated legal entities of Immucor
Immucor operates through Immucor India Private Limited (amalgamated). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Immucor India Private Limited CIN U85190DL2012FTC232632 | Amalgamated | 10 Mar 2012 | New Delhi, Delhi | ₹68.6 Cr | 44 | 3 | View details |
Apps and channels of Immucor
its YouTube channel Werfen_NA has 730 subscribers and 30 videos.
Videos from Immucor
The most watched videos on Immucor's YouTube channel, Werfen_NA (730 subscribers). Click a video to play it here.
More on Werfen_NA.
Funding Insights of Immucor
- Total Rounds 1
All 1 funding rounds of Immucor with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | – | Debt – Conventional | – | – | – |
3 investors in total: 3 institutional.
Investors in Immucor
Immucor has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include TPG, Werfen and The Riverside Company.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and debt are provided to middle market companies. | – | riversidecompany.com | Cleveland, United States | |
Fund of funds focused on pre-seed and seed-stage companies | 1992 | tpg.com | Fort Worth, United States | |
Global leader for In Vitro Diagnostic | 1959 | werfen.com | Barcelona, Spain |
Investor details for Immucor
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Immucor India Private Limited (Immucor)
Immucor India Private Limited is the primary company behind Immucor. The board of Immucor India Private Limited currently have 3 directors; the longest-serving is Vishal Gupta, appointed in 2015. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Vishal Gupta DIN 06748601 | Whole-time director | 09 Jan 2015 | 11 yrs 8 mo | Immucor India Private Limited |
| Anurag Kumar Mishra DIN 08024343 | Additional Director | 27 Nov 2024 | 1 yr 10 mo | Immucor India Private Limited |
| Borja Alvarez Frade DIN 10829043 | Additional Director | 27 Nov 2024 | 1 yr 10 mo | Immucor India Private Limited |
People of Immucor
52 people are tracked at Immucor (8 in leadership, 44 in team).
| Name | Role | Group |
|---|---|---|
Avi Pelossof | CEO & President | Leadership |
Bryan Marshall | Director, Manufacturing Engineering And Process Support | Leadership |
Gary Lawson | Senior Director, Quality Systems And Field Quality | Leadership |
Keita Enshu | President | Leadership |
Ken Stewart | Sr. Director, Human Resources | Leadership |
William Cork | Chief Technology Officer | Leadership |
Hans Lee | VP Of R&d Transplant | Leadership |
Mohamed Jalloh | Director Of Internal Audit | Leadership |
Tayla Ramsay | Corporate Events & Tradeshow Manager | Team |
Connie Wilson | Quality Assurance Manager | Team |
Andrea Carr | Blood Bank Business Manager | Team |
Bart MacGillivray | Blood Bank Business Manager | Team |
Charles Jackson | Blood Bank Business Manager | Team |
Clare L. | Manager Of Biologics Procurement And Manufacturing Training | Team |
Courtney Burch Bs | Blood Bank Business Manager | Team |
Diane Esagui | Blood Bank Business Manager | Team |
Eric Mills | Supervisor, Field Quality | Team |
Denise Barilli | Blood Bank Business Manager | Team |
Charlotte Parent | Marketing Manager, France & Benelux | Team |
Michael Quam | Principal Systems Engineer | Team |
32 more people are available in the full profile.
Complete people profiles for Immucor
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Immucor
Figures of Immucor India Private Limited, the primary company behind Immucor, for FY 2024. Revenue was ₹68.59 Cr (+12% year on year). Net profit was ₹3.17 Cr (5% margin). EBITDA was ₹10.02 Cr (15% margin). Revenue has grown at a compounded annual rate of +20% over three years and +10% over five years.
- ₹68.59 CrRevenue · FY 2024 · +12% YoY
- ₹3.17 CrNet profit · 5% margin
- ₹10.02 CrEBITDA · 15% margin
- ₹4.18 CrPaid-up capital
- 44Employees (provident fund records)
- +20%Revenue CAGR, 3 years
- +10%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Immucor India Private Limited are on its company page.
Detailed financial statements for Immucor
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Immucor
Immucor has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include BioArray Solutions and Organ-i.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Molecular diagnostics for organ rejection in transplant patients are developed. | organ-i.com | Palo Alto, United States | 2010 | May 2015 | $6.8M | |
Bead-based assays for nucleic acid and protein analysis are developed. | bioarrays.com | New York, United States | 2001 | Mar 2008 | $117M |
Complete acquisition details for Immucor
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Immucor
7 dated milestones of Immucor across 40 years, from founding to its latest funding, stage changes and deals.
- Founded Immucor is founded.
- Acquisition Acquires BioArray Solutions.
- Exit Acquired by Riverside.
- Exit Acquired by TPG.
- Acquisition Acquires Organ-i.
- Funding First funding round.
- Exit Acquired by Werfen.
Competitors of Immucor
Immucor operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| lifeminetx.com | 2016 | Cambridge, United States | $300.07M | 85 | Developer of novel drugs from fungi via genome mining and recombinant overexpression |
Detailed competitors of Immucor
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Immucor
The website of Immucor (immucor.com) receives about 2.5K visits a month.
- Monthly visits2.5K
▼ 47.1% vs previous month
Websites whose visitors overlap most with Immucor. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| haemonetics.com | 100% | 50.5K | #632,767 | View details | |
nybloodcenter.org | nybloodcenter.org | 99% | – | – | – |
| crbard.com | 94% | – | – | View details | |
qsii.com | qsii.com | 82% | – | – | – |
| alcon.com | 82% | 171K | #286,128 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 22 similar websites and full traffic analytics for Immucor
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 22 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Immucor
Complete news archive for Immucor
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Immucor
10 companies that operate in the same segment as Immucor (Transplant Medicine), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medical solutions for transplant patients are developed and provided. | 1998 | Brisbane, California, United States | USD 138.21 M | USD 379.81 M | 650 | |
Developer of organ transplantation technology | 1998 | Andover, Massachusetts, United States | USD 265.55 M | USD 605.49 M | 728 | |
Warm storage and transport systems for harvested organs are provided. | 2008 | Oxford, Oxfordshire, United Kingdom | USD 45.42 M | USD 1.36 M | 14 | |
Human tissue-based products are developed for vascular disease applications. | 2004 | Morrisville, United States | USD 424.76 M | USD 2.04 M | 220 | |
Next-generation medicines for CNS and immunological disorders are developed. | 2007 | New York, New York, United States | USD 4.45 M | USD 13.11 M | 81 | |
Breakthrough therapies are developed for blood diseases and infections. | 2014 | Buffalo, New York, United States | USD 1 M | – | 22 | |
Personalized skin tissue therapy is developed by CUTISS for surgeries. | 2017 | Zurich, Switzerland | USD 94.37 M | – | – | |
Game currency trading services are provided by Magenta Piman. | 2016 | Cambridge, Massachusetts, United States | USD 150.5 M | – | 75 | |
T regulatory cell therapies are developed for immunological diseases. | 2019 | London, England, United Kingdom | USD 344.25 M | – | – | |
Therapeutics for transplantation in autoimmune and neurodegenerative diseases are developed. | 2004 | Irvine, California, United States | USD 1.89 M | – | 31 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Immucor
Immucor was founded in 1982 and raised its 1st funding round 38 years after it was founded.
Immucor is headquartered in United States.
Avi Pelossof is the current CEO of Immucor.
The primary company behind Immucor, Immucor India Private Limited, reported revenue of ₹68.59 Cr for FY 2024, up 12% year on year.
Immucor was founded in 1982 in the United States and operates within the healthcare sector, focusing on diagnostics for transfusion and transplantation. A variety of products is offered, including reagents, capture technologies, automation systems for blood banks, software solutions, and molecular testing tools. These offerings support clinical and laboratory operations in blood management and organ transplantation processes.
Immucor's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Immucor has made 2 acquisitions, including BioArray Solutions, and Organ-i.
Immucor has 3 investors. Key investors include TPG, Werfen, and The Riverside Company.
Immucor operates through Immucor India Private Limited.
Yes. Immucor was acquired by Werfen in November 2022.
The legal entities of Immucor currently have 3 directors, including Vishal Gupta, Anurag Kumar Mishra, Borja Alvarez Frade.